RyboDyn

RyboDyn is a biotechnology company that is pioneering the development of first-class immunotherapies targeting the dark genome. By leveraging proprietary sequencing methods and the advanced bioinformatics platform RyboCypher, RyboDyn™ is discovering and validating previously unknown proteins and disease-specific targets. With its scalable internal platform for lead discovery and optimization, as well as proprietary IP licensed from Oregon Health & Science University, RyboDyn is advancing a unique "target-to-asset" approach to development. The company collaborates with leading clinical and academic institutions, as well as biopharmaceutical partners, to validate and advance its drug pipeline, focusing on providing transformative solutions for cancer and other diseases with unmet medical needs.